Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC.BCLI · Entity 7869 | Director | December 10, 2021 | December 11, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRAINSTORM CELL THERAPEUTICS INC.
Report date December 10, 2021 · Filed December 11, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,323 |
Reported balance
After 2021-12-10 transaction · row 1
1 source rowRow 1 · 2021-12-10 · Grant · Acquired 6,666 · Balance 11,323 F1: Shares acquired are shares of restricted stock awarded pursuant to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan. The shares of restricted stock vested in 12 consecutive, equal monthly installments commencing on the one month anniversary of April 6, 2021 until fully vested on the 12 month anniversary of April 6, 2021, provided that the Reporting Person remained a member of the Board of Directors of the Issuer on each vesting date. |
| Common StockSEC Table I · non-derivative | IndirectAbbhi Investments, LLC | 2,164,530 |
Reported balance
Holding disclosure · report date 2021-12-10 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 2,164,530 F2: Abbhi Investments, LLC is the record owner of these securities. Mr. Sankesh Abbhi is the manager of Abbhi Investments, LLC and maintains sole voting and investment power with respect to common stock and warrants held by Abbhi Investments, LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares acquired are shares of restricted stock awarded pursuant to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan. The shares of restricted stock vested in 12 consecutive, equal monthly installments commencing on the one month anniversary of April 6, 2021 until fully vested on the 12 month anniversary of April 6, 2021, provided that the Reporting Person remained a member of the Board of Directors of the Issuer on each vesting date.
F2: Abbhi Investments, LLC is the record owner of these securities. Mr. Sankesh Abbhi is the manager of Abbhi Investments, LLC and maintains sole voting and investment power with respect to common stock and warrants held by Abbhi Investments, LLC.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 10, 2021 Filed Dec 11, 2021 01:02 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 6,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-148748 · tm2135032-3_4.xml · nonDerivative · entry 1 Abbhi Sankesh · CIK 0001806887 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,323 F1 · shares: Shares acquired are shares of restricted stock awarded pursuant to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan. The shares of restricted stock vested in 12 consecutive, equal monthly installments commencing on the one month anniversary of April 6, 2021 until fully vested on the 12 month anniversary of April 6, 2021, provided that the Reporting Person remained a member of the Board of Directors of the Issuer on each vesting date. Read SEC document |
| July 15, 2020 Filed Jul 16, 2020 21:15 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | PurchaseCommon Stock | 46,779 | $12.99 | $607,659.21 |
DisclosureSEC source: 0001104659-20-084127 · tm2024951d1_form4.xml · nonDerivative · entry 2 Abbhi Sankesh · CIK 0001806887 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Abbhi Investments, LLC Disclosed balance after: 2,164,530 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.82 to $13.14, inclusive. The Reporting Person undertakes to provide to the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Abbhi Investments, LLC is the record owner of these securities. Mr. Sankesh Abbhi is the manager of Abbhi Investments, LLC and maintains sole voting and investment power with respect to common stock and warrants held by Abbhi Investments, LLC. Read SEC document |
| April 06, 2020 Filed Apr 7, 2020 22:12 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 4,657 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-044267 · tm2014134d2_form4.xml · nonDerivative · entry 1 Abbhi Sankesh · CIK 0001806887 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,657 F1 · shares: Shares acquired are shares of restricted stock awarded pursuant to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on the one month anniversary of the date of grant until fully vested on the 12 month anniversary of the date of grant, provided that the Reporting Person remains a member of the Board of Directors of the Issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.